Jasper Therapeutics (NASDAQ:JSPR) Coverage Initiated by Analysts at UBS Group

UBS Group initiated coverage on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research report released on Monday morning, Marketbeat reports. The brokerage issued a neutral rating on the stock.

A number of other equities analysts also recently issued reports on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Thursday, January 22nd. Rodman & Renshaw started coverage on Jasper Therapeutics in a report on Tuesday, January 13th. They issued a “buy” rating and a $17.00 target price on the stock. Six research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $19.88.

Jasper Therapeutics Price Performance

NASDAQ:JSPR opened at $1.19 on Monday. Jasper Therapeutics has a one year low of $1.11 and a one year high of $7.19. The company has a market cap of $33.30 million, a PE ratio of -0.20 and a beta of 3.08. The firm has a 50-day moving average of $1.38 and a 200-day moving average of $1.83.

Hedge Funds Weigh In On Jasper Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Velan Capital Investment Management LP lifted its holdings in Jasper Therapeutics by 86.1% during the third quarter. Velan Capital Investment Management LP now owns 2,668,395 shares of the company’s stock worth $6,206,000 after acquiring an additional 1,234,567 shares during the period. Goldman Sachs Group Inc. grew its stake in Jasper Therapeutics by 6,394.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,746,492 shares of the company’s stock valued at $3,196,000 after purchasing an additional 1,719,602 shares during the period. Acorn Capital Advisors LLC bought a new position in Jasper Therapeutics in the 3rd quarter valued at $3,291,000. Kingdon Capital Management L.L.C. increased its position in shares of Jasper Therapeutics by 93.5% during the 3rd quarter. Kingdon Capital Management L.L.C. now owns 1,324,845 shares of the company’s stock valued at $3,153,000 after purchasing an additional 640,138 shares during the last quarter. Finally, Millennium Management LLC raised its stake in shares of Jasper Therapeutics by 194.2% during the 4th quarter. Millennium Management LLC now owns 1,073,783 shares of the company’s stock worth $1,965,000 after purchasing an additional 708,844 shares during the period. Hedge funds and other institutional investors own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.